Trial Profile
Phase II Study of Four Concentrations of Intraperitoneal NanoPac Plus Six Cycles of IV Carboplatin and Paclitaxel in Patients With Platinum-Sensitive Recurrent Stage III Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Ovarian cancer
- Focus Adverse reactions
- Sponsors Nanology
- 06 Jun 2023 Results of 7 studies (NCT00666991, NCT03636256, NCT03077659, NCT04221828, NCT03029585, NCT03077685, NCT04314895) assessing safety findings in subjects co-administered LSAM-PTX or LSAM-DTX and common SOC therapies for treatment of carcinomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 31 Mar 2021 Status changed from completed to discontinued.
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.